Proteins get decorated

The previous parts of this series looked at ways chemists change the shape and stability of peptides: bridges, rings, methyl groups, fatty tails. This final part is about two modifications nature uses constantly to change what proteins do: adding phosphate and adding sugar.

Two chapters of Peptide Synthesis and Applications cover how chemists recreate these in the lab. Both explain something important about how your cells work, and where some future medicines may come from.

Phosphate: the on/off switch

Chapter 13, by Kim Højlys-Larsen and Knud Jensen, explains that phosphorylation often controls whether a protein is active or inactive. Adding a phosphate group to a serine, threonine, tyrosine (or histidine) changes the protein's shape, activity, binding partners and location in the cell.

The numbers show how central it is. The chapter notes the human genome contains 518 protein kinase domains, the enzymes that add phosphates, making up about 2% of the genome, and roughly 204 phosphatases, the enzymes that remove them. The constant interplay between the two controls metabolism, transport across membranes, gene activity, and chains of signalling where one kinase activates the next.

The chapter includes a revealing comparison: a search for "protein phosphorylation" in the PubMed research database returned more than 186,000 papers, while "phosphopeptide synthesis" returned only about 4,600. Huge interest in the biology, relatively few people making the tools.

Many important cancer drugs are kinase inhibitors, which block specific kinases that have gone out of control. Synthetic phosphopeptides are among the tools researchers use to study how kinases and phosphatases recognise their targets, and to raise antibodies that detect whether a specific protein has been phosphorylated.

The chemistry problem with phosphate

Making phosphopeptides is tricky. The chapter explains that when early chemists used a doubly protected phosphoserine in Fmoc chemistry, the base used to remove the Fmoc cap caused part of the phosphate to be lost, leaving a damaged residue called dehydroalanine.

The fix was a monobenzyl protecting group on the phosphate, which minimised that loss and made Fmoc synthesis of phosphopeptides the preferred method. Phosphopeptides cannot be made by the older Boc method at all, because its harsh acid final step strips the phosphate off.

The chapter's own approach builds phosphopeptides on a special resin (PEGA) through a backbone linker, so the side-chain protection can be removed while the peptide stays attached. That lets researchers use the peptide still on its bead to "fish" for proteins that bind to it.

Sugar: the most complex decoration

Chapter 14, by Ola Blixt and Emiliano Cló (the latter from Novo Nordisk), covers glycosylation, the attachment of sugars, which the chapter describes as one of the most complex modifications in nature.

There are two main types. N-glycosylation attaches sugars to asparagine at a recognisable sequence motif. O-glycosylation attaches them to serine or threonine, with no clear consensus sequence and many different starting sugars, making it far more variable.

The chapter's table of O-glycosylation types shows how varied the roles are:

  • Mucin-type glycosylation, the most common in the body, coats proteins in dense sugar clusters.
  • Xylose-linked chains form the core of proteoglycans like heparan sulfate, key components of the tissue surrounding cells.
  • O-GlcNAc, a single sugar added inside cells, which often works alongside phosphorylation and is implicated in cancer, neurodegeneration and diabetes.
  • O-mannose, essential for muscle cells to connect to their surroundings. Genetic defects in it cause forms of muscular dystrophy.
  • O-fucose and O-glucose, found on the Notch signalling protein that controls cell fate.

Sugars, cancer and vaccines

The part I found most interesting is about the immune system. The chapter explains that many antibodies against tumour-associated sugar markers (with names like Tn, T and STn) need the sugar presented together with the underlying peptide to bind properly. Cancer cells often glycosylate their proteins abnormally, and this abnormal glycosylation can break the immune system's tolerance, producing antibodies that recognise these specific glycopeptides.

That observation underpins efforts to develop blood tests that detect those antibodies as cancer markers, and cancer vaccines that train the immune system to recognise tumour-specific glycopeptides.

To search for these antibodies, the chapter describes building glycopeptide microarrays: glass slides spotted with hundreds of different synthetic glycopeptides, which can be exposed to a blood sample to see what binds. One clever trick: during synthesis, any chains that fail to add an amino acid are chemically capped so they cannot attach to the slide. Only the full-length product sticks, effectively purifying it on the slide itself.

Why chemical synthesis matters here

The chapter explains why chemists make glycopeptides by synthesis rather than using enzymes: enzymatic glycosylation often gives incomplete reactions and uncertain attachment sites, producing mixtures. Chemical synthesis gives control over exactly which site carries which sugar, producing a single, defined molecule. For research, and for any future diagnostic or vaccine, that precision is essential.

Where the whole series lands

Across these eight parts, we have seen that a peptide is rarely just a straight chain of amino acids. It can be stitched from pieces, locked by disulfide bridges, tied into knots, closed into rings, methylated, rebuilt as a peptoid, given a fatty tail, and decorated with phosphates and sugars. Each change alters how it folds, how long it lasts, what it binds, and whether the body can see it.

That is the leverage this series offers you: the understanding that two peptides with similar names, or even similar sequences, can be profoundly different molecules. When anyone describes a peptide product, the right questions are not only "what is the sequence?" but also "how is it modified, how was it made, and how was that verified?" Those are the questions the scientists in this book ask about every molecule they make.

This series explains laboratory chemistry for general readers. It is not a guide to making or using any compound. Nothing here is medical advice.